PURIFIED POLYSACCHARIDES ANTIGEN CONJUGATED clinical trials

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease

This study is testing a new pneumonia vaccine called V116. It's for adults aged 18-64 who are at higher risk of getting pneumonia. We want to see how safe it is, if people can tolerate it well, and how good it is at fighting off the infection compared to existing vaccines.